2,438 reports of this reaction
1.5% of all ESTRADIOL reports
#14 most reported adverse reaction
BREAST CANCER FEMALE is the #14 most commonly reported adverse reaction for ESTRADIOL, manufactured by Allergan, Inc.. There are 2,438 FDA adverse event reports linking ESTRADIOL to BREAST CANCER FEMALE. This represents approximately 1.5% of all 159,657 adverse event reports for this drug.
Patients taking ESTRADIOL who experience breast cancer female should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BREAST CANCER FEMALE is a less commonly reported adverse event for ESTRADIOL, but still significant enough to appear in the safety profile.
In addition to breast cancer female, the following adverse reactions have been reported for ESTRADIOL:
The following drugs have also been linked to breast cancer female in FDA adverse event reports:
BREAST CANCER FEMALE has been reported as an adverse event in 2,438 FDA reports for ESTRADIOL. This does not prove causation, but indicates an association observed in post-market surveillance data.
BREAST CANCER FEMALE accounts for approximately 1.5% of all adverse event reports for ESTRADIOL, making it a notable side effect.
If you experience breast cancer female while taking ESTRADIOL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.